Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo.

Huber, C.; Bobek, N.; Kuball, J.; Thaler, S.; Hoffarth, S.; Theobald, M.; Schuler, M.

Deregulation of apoptosis signalling is commonly found in cancer and results in resistance to cytotoxic therapies. Immunotherapy is a promising strategy to eliminate resistant cancer cells. The transfer of T-lymphocytes during allogeneic stem cell transplantation is clinically explored to induce a‘graft-versus-tumor’effect (GvT). Cytotoxic T-lymphocytes (CTL), which are major effectors of GvT, eliminate cancer cells by inducing apoptosis via multiple parallel pathways. Here, we study in vitro and in vivo the susceptibility of murine cancer cells engineered to express single antiapoptotic genes to CTL-mediated cytotoxicity. Interestingly, we find that single inhibitors of caspase activation, such as BCL-XL or dominant-negative mutants of FADD and caspase-9, protect cancer cells against antigen-specific CTL in vitro. Moreover, expression of BCL-XL impairs the growth suppression by adoptively transplanted CTL of established tumours in vivo. Hence, apoptosis defects that provide protection to cytotoxic cancer therapies can confer crossresistance to immunotherapy by tumour-reactive CTL.Cell Death and Differentiation (2005) 12, 317-325. doi:10.1038/sj.cdd.4401563 Published online 28 January 2005

T cells; TUMORS; CANCER; APOPTOSIS; CELL death; CELL differentiation

Cell Death & Differentiation, 2005, Vol 12, Issue 4, p317

1350-9047

Academic Journal

10.1038/sj.cdd.4401563